From Discovery to Delivery: How Piramal Pharma Limited is Strengthening its Drug Development Capabilities

One of the most recent changes at Piramal Pharma Limited is the expansion of its U.S. facility, doubling sterile fill-finish capacity and adding commercial-scale lyophilization to meet growing demand for U.S. containment and antibody-drug conjugate (ADC) support. The company has also enhanced its Science Collective by onboarding senior leaders in discovery and small molecule chemistry, enabling deeper technical collaboration with clients across modalities such as peptides, small molecules, and ADCs. Lastly, their global sustainability and digitalization initiatives have shifted to support future AI-driven manufacturing and quality solutions.

Learn More About:

• How Piramal as a leading global CDMO is expanding to meet market demands and patient needs
• Their seamless integration of facilities and expert team of industry leaders, enabling them to provide comprehensive services across the entire drug life cycle
• The role of patient centricity at the heart of their operations, with a goal to reduce the burden of disease for patients worldwide